Profile data is unavailable for this security.
About the company
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
- Revenue in USD (TTM)173.82m
- Net income in USD-168.32m
- Incorporated1993
- Employees486.00
- LocationFibroGen Inc409 ILLINOIS STREETSAN FRANCISCO 94158United StatesUSA
- Phone+1 (415) 978-1200
- Fax+1 (415) 978-1902
- Websitehttps://www.fibrogen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quince Therapeutics Inc | 0.00 | -53.12m | 30.29m | 32.00 | -- | 0.645 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
Raphael Pharmaceutical Inc | 0.00 | -1.40m | 30.86m | 0.00 | -- | -- | -- | -- | -0.0803 | -0.0803 | 0.00 | -0.0155 | 0.00 | -- | -- | -- | -1,134.41 | -- | -- | -- | -- | -- | -- | -- | -- | -139.10 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
Elevation Oncology Inc | 0.00 | -39.70m | 30.88m | 29.00 | -- | 0.3528 | -- | -- | -0.8399 | -0.8399 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -35.30 | -- | -37.14 | -- | -- | -- | -- | -- | -- | -25.25 | 0.2765 | -- | -- | -- | 51.93 | -- | -- | -- |
AN2 Therapeutics Inc | 0.00 | -64.66m | 31.04m | 41.00 | -- | 0.3154 | -- | -- | -2.26 | -2.26 | 0.00 | 3.30 | 0.00 | -- | -- | 0.00 | -62.35 | -- | -69.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
Lumos Pharma Inc | 1.49m | -35.75m | 31.28m | 33.00 | -- | 3.04 | -- | 21.05 | -4.43 | -4.43 | 0.1841 | 1.26 | 0.0382 | -- | 7.41 | 45,030.30 | -91.98 | -29.78 | -107.92 | -32.32 | -- | -- | -2,405.72 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 31.42m | 163.00 | -- | 0.154 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Ocean Biomedical Inc | 0.00 | -98.59m | 31.57m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
FibroGen Inc | 173.82m | -168.32m | 32.97m | 486.00 | -- | -- | -- | 0.1897 | -1.71 | -1.71 | 1.76 | -2.31 | 0.4301 | 1.22 | 44.10 | 357,644.00 | -42.40 | -30.62 | -89.79 | -42.31 | 76.65 | 93.52 | -98.60 | -119.08 | 1.24 | -12.47 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
Xilio Therapeutics Inc | 2.36m | -65.53m | 33.06m | 73.00 | -- | 0.9894 | -- | 14.03 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
Estrella Immunopharma Inc | 0.00 | -7.31m | 33.54m | -- | -- | 7.87 | -- | -- | -0.1977 | -0.1977 | 0.00 | 0.1178 | 0.00 | -- | -- | -- | -195.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 33.95m | 4.00 | -- | 9.75 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
Unicycive Therapeutics Inc | 0.00 | -24.41m | 33.96m | 14.00 | -- | -- | -- | -- | -0.2843 | -0.2843 | 0.00 | 0.7193 | 0.00 | -- | -- | 0.00 | -68.77 | -218.20 | -118.93 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
Dyadic International Inc | 1.80m | -7.74m | 34.78m | 7.00 | -- | 10.98 | -- | 19.28 | -0.2675 | -0.2675 | 0.0624 | 0.1075 | 0.1662 | -- | 3.55 | 257,731.40 | -71.33 | -36.82 | -87.19 | -39.85 | 50.01 | 22.47 | -429.07 | -410.16 | -- | -- | 0.6324 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
Tempest Therapeutics Inc | 0.00 | -31.75m | 35.04m | 17.00 | -- | 2.01 | -- | -- | -1.64 | -1.64 | 0.00 | 0.6921 | 0.00 | -- | -- | 0.00 | -87.09 | -57.10 | -127.72 | -71.20 | -- | -- | -- | -- | -- | -368.16 | 0.3861 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Surrozen Inc | 0.00 | -53.45m | 35.81m | 42.00 | -- | 5.91 | -- | -- | -21.74 | -21.74 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -98.01 | -- | -110.62 | -- | -- | -- | -- | -- | -- | -2.05 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
PRIMECAP Management Co.as of 30 Jun 2024 | 13.66m | 13.73% |
Armistice Capital LLCas of 31 Mar 2024 | 7.94m | 7.98% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.43m | 6.47% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 6.36m | 6.39% |
Acadian Asset Management LLCas of 30 Jun 2024 | 3.36m | 3.38% |
Jacobs Levy Equity Management, Inc.as of 31 Mar 2024 | 2.21m | 2.22% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.16m | 2.17% |
683 Capital Management LLCas of 31 Mar 2024 | 1.85m | 1.86% |
Citadel Advisors LLCas of 31 Mar 2024 | 1.57m | 1.58% |
Two Sigma Advisers LPas of 31 Mar 2024 | 1.20m | 1.21% |